Spirox

Spirox EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Spirox (3055.TW) as of Oct 3, 2026 is -346.59 M TWD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -291.00 M TWD — a change of 19.11% (lower).

EBITDA

-346.59 MTWD

YoY

19.11%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Spirox is 2026 -346.59 M TWD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Spirox was 2025 -291.00 M TWD. It decreases by 19.11% lower compared to the previous year.

The Spirox EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
66.23 M TWD
Jan 1, 2019
55.09 M TWD
Jan 1, 2020
21.45 M TWD
Jan 1, 2021
-324.67 M TWD
Jan 1, 2022
344.65 M TWD
Jan 1, 2023
-162.44 M TWD
Jan 1, 2024
-291.00 M TWD
Jan 1, 2025
-346.59 M TWD
The Spirox EBITDA history
YEAREBITDAYoY
-346.59 MTWD+19.11%
-291.00 MTWD+79.14%
-162.44 MTWD-147.13%
344.65 MTWD-206.15%
-324.67 MTWD-1,613.55%
21.45 MTWD-61.06%
55.09 MTWD-16.82%
66.23 MTWD+13.52%
58.34 MTWD-66.99%
176.73 MTWD+116.78%
81.53 MTWD-72.72%
298.82 MTWD—
Access this data via the Eulerpool API

Spirox Stock analysis

What does Spirox do? The Spirox Corporation is a company that was founded in 2007 and is headquartered in Menlo Park, California. The company operates in the medical technology industry and specializes in the development of products for nasal breathing. The mission of Spirox is to help people who have difficulty breathing through their nose. The company has recognized that many people have difficulty breathing through their nose due to congestion or other issues. Breathing through the mouth, however, can lead to a range of health problems such as dry mouth, sleep apnea, and respiratory infections. Therefore, Spirox has set out to develop innovative solutions to facilitate nasal breathing. Spirox's products include both implantable and non-implantable solutions. The company has a small but effective product portfolio consisting of two products: the Latera Nasal Stent and the AeroForm Nasal Stent. The Latera Nasal Stent is used to permanently open the nasal passages and facilitate breathing. The placement of the stent is a minimally invasive procedure that is typically performed on an outpatient basis. The Latera Nasal Stent is inserted and secured in the nasal wings to allow for better airflow through the nostrils. The stent is made of polydioxanone (PDO), a biocompatible polymer fiber that is absorbed by the body. Spirox's second product, the AeroForm Nasal Stent, is a non-implantable nasal stent used for temporary relief of nasal breathing. The AeroForm is a soft stent made of a flexible polymer material. It is inserted into the nasal passages and forms a gentle expansion to facilitate nasal breathing. As a company, Spirox focuses on collaboration with specialists and clinics to ensure that their products have high success rates. The company has established a partnership with the American Academy of Otolaryngology - Head and Neck Surgery (AAO-HNS) to advance scientific research and development in the nasal breathing industry. Spirox is led by experienced executives from the medical technology industry. The CEO, Duke Rohlen, has over 20 years of experience in leading medical technology companies such as Inspire Medical Systems and CV Ingenuity. The board team also includes Elektra Papadopoulos as Chair of the Board, who has worked at Hologic and Boston Scientific, among others. Although Spirox is a relatively small company, it has already received several awards. In 2017, the company was awarded the Red Herring Top 100 North America Award, which recognizes companies that are leading in the innovation industry. Overall, Spirox is an emerging company in the medical technology industry that offers innovative solutions to facilitate nasal breathing. Through collaboration with doctors and clinics and a focus on scientific research, the company aims to improve the success and effectiveness of its products. Spirox is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Spirox stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Spirox is -346.59 M TWD in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Spirox changed from -291.00 M TWD to -346.59 M TWD, representing a 19.11% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Spirox since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Spirox historically and in real time.

Access this data via the Eulerpool API

Income Statement — Spirox

All Key Metrics — Spirox